February 07, 2016 – The European Commission has approved once-daily Osimertinib (Tagrissa) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) that is positive for the epidermal growth-factor receptor (EGFR) T790M mutation. This follows a positive review in …

Osimertinib (Tagrissa) approved for non-smal cell lung cancer (NSCLC) patient subgroup carrying the EGFR T790M mutation Read more »

January 20, 2016 – The American Food and Drug Administration (FDA) just approved Ofatumumab (Arzerra)  Injection for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL). Ofatumumab, also …

Ofatumumab (Arzerra) approved for recurrent or progressive chronic lymphocytic leukemia (CLL) Read more »

Treatment of submental fat: Before and after

May 09, 2015 – The U.S. Food and Drug Administration (FDA) recently approved Kybella (deoxycholic acid) as treatment for adults with moderate-to-severe fat below the chin, known as submental fat (i.e., located in the submental triangle). Using Kybella for the …

Closer to the ideal of beauty: Deoxycholic Acid (Kybella) as a treatment for fat below the chin approved Read more »